Genzyme's Campath performs well in MS study

Genzyme is touting the interim data from a head-to-head study that compares its drug Campath against Serono's Rebif for treating multiple sclerosis. Researchers claim that Campath patients demonstrated a lower rate of relapse and significantly reduced the rate of progression to disability. Campath is currently approved as a therapy for leukemia and Genzyme is pushing to expand its approval to MS. The two-year Phase II trial included 334 patients.

- see the release on the Campath trial

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.